Sophie Billioti de Gage

French National Agency for Medicines and Health Products Safety

Presentation(s):

• OP-22A - Risk of Myocardial Infarction, Stroke or Death in New Users of Intravitreal Aflibercept versus New Users of Intravitreal Ranibizumab: A Nationwide Cohort Study

  Monday, August 23, 2021
  1:45 PM – 3:30 PM US Eastern Time